Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KarXT
Biotech
Neurocrine's KarXT rival hits in phase 2—but only at low dose
Neurocrine achieved its hoped-for profile in the schizophrenia trial but only saw efficacy at the lowest dose—the three higher doses all failed.
Nick Paul Taylor
Aug 28, 2024 7:53am
BMS' schizophrenia drug shows long-term benefit with new data
Apr 6, 2024 1:15pm
UPDATE: Bristol Myers Squibb unwraps $14B deal for Karuna
Dec 22, 2023 7:32am
Karuna's schizophrenia drug set for FDA decision in Q3 2024
Nov 29, 2023 10:00am
Karuna's journey from 'serendipitous clinical finding' to FDA
Oct 4, 2023 6:00am
Hype builds for Karuna's schizophrenia drug with phase 3 data
Mar 20, 2023 12:03pm
